Tolera Therapeutics

About:

Tolera Therapeutics is a spin-off of the Cleveland Clinic focused on bringing specific and safer therapies to treat various diseases.

Website: http://www.tolera.com

Top Investors: Hopen Life Science Ventures, Triathlon Medical Venture Partners

Description:

Tolera Therapeutics Inc., founded under the scientific and medical direction of Maria Siemionow, M.D., Ph.D., D.Sc., is a spin-off of the Cleveland Clinic focused on bringing more specific, and safer therapies to market with competitive speed. The company’s technology stems from immune modulation and transplant research done at the Cleveland Clinic under the leadership of Dr. Siemionow, an internationally recognized leader in the fields of microsurgery and transplantation. In addition to her surgical skills, she has focused her research efforts on the development of therapies to promote life-long acceptance of organ and tissue transplants, while reducing or eliminating the need for chronic immunosuppression therapies and their dangerous side effects. In addition, Dr. Siemionow’s efforts have led to new discoveries in immune system modulation. She has authored and contributed to over 180 peer reviewed articles on transplantation, immune suppression and organ tolerance.

Total Funding Amount:

$12.3M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Kalamazoo, Michigan, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)tolera.com

Founders:

Jim Herrmann, John J. Puisis

Number of Employees:

11-50

Last Funding Date:

2014-09-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai